Given that SGLT-1 inhibition enhances GLP-1 secretion and DPP-4 inhibition prolongs endogenous GLP-1 half-life, a synergic effect on glucose control in type 2 diabetes is to be expected. The gene discussed is GCG; the disease is type 2 diabetes mellitus.